Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPI-7711 + itraconazole
- Development stage
- Unknown
- Lead developer
- Beta Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BPI-7711 + itraconazole is a **combination regimen** of rezivertinib (BPI-7711), a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), and itraconazole, an antifungal agent known to be a potent inhibitor of the cytochrome P450 enzyme CYP3A4. BPI-7711 (rezivertinib) selectively and irreversibly inhibits both sensitizing and T790M-resistant EGFR mutations and is indicated primarily for EGFR-mutated non-small cell lung cancer (NSCLC). Itraconazole may be used in combination for pharmacokinetic interaction studies, as it can increase blood levels of BPI-7711 by inhibiting its metabolism through CYP3A4 inhibition. This combination is used in clinical pharmacology studies to evaluate drug-drug interactions, but is not a therapeutic fixed-dose combination for any indication.
- Brand names
- rezivertinib
- Other names
- rezivertinib + itraconazole
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on BPI-7711 + itraconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPI-7711 + itraconazole.